Jaguar Health (NASDAQ:JAGX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Jaguar Health (NASDAQ:JAGX) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

Jaguar Health Stock Performance

NASDAQ JAGX opened at $1.16 on Tuesday. The firm’s 50 day simple moving average is $3.45 and its 200 day simple moving average is $6.14. The company has a current ratio of 1.89, a quick ratio of 1.39 and a debt-to-equity ratio of 1.84. Jaguar Health has a 1 year low of $1.11 and a 1 year high of $37.50.

Jaguar Health (NASDAQ:JAGX) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($3.60) earnings per share for the quarter. The business had revenue of $2.35 million during the quarter. Jaguar Health had a negative net margin of 377.95% and a negative return on equity of 642.15%. On average, equities analysts expect that Jaguar Health will post -0.69 earnings per share for the current fiscal year.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.